KAYEXALATE Drug Patent Profile
✉ Email this page to a colleague
When do Kayexalate patents expire, and what generic alternatives are available?
Kayexalate is a drug marketed by Concordia and is included in one NDA.
The generic ingredient in KAYEXALATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kayexalate
A generic version of KAYEXALATE was approved as sodium polystyrene sulfonate by CMP PHARMA INC on January 19th, 1989.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KAYEXALATE?
- What are the global sales for KAYEXALATE?
- What is Average Wholesale Price for KAYEXALATE?
Summary for KAYEXALATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 3 |
| Drug Prices: | Drug price information for KAYEXALATE |
| DailyMed Link: | KAYEXALATE at DailyMed |
Recent Clinical Trials for KAYEXALATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, Irvine | Phase 4 |
| Nephrology Research Axis of Maisonneuve Rosemont Hospital | Phase 4 |
| Maisonneuve-Rosemont Hospital | Phase 4 |
US Patents and Regulatory Information for KAYEXALATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordia | KAYEXALATE | sodium polystyrene sulfonate | POWDER;ORAL, RECTAL | 011287-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
